These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32321714)

  • 1. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
    Tang B; Chi Z; Chen Y; Liu X; Wu D; Chen J; Song X; Wang W; Dong L; Song H; Wu H; Feng H; Yao S; Qin S; Zhang X; Guo J
    Clin Cancer Res; 2020 Aug; 26(16):4250-4259. PubMed ID: 32321714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.
    Tang B; Duan R; Zhang X; Qin S; Wu D; Chen J; Yao H; Chi Z; Guo J; Yan X
    Oncologist; 2024 Jun; 29(6):e822-e827. PubMed ID: 38547052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
    J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
    Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
    J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
    Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
    J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
    Sheng X; Chen H; Hu B; Yao X; Liu Z; Yao X; Guo H; Hu Y; Ji Z; Luo H; Shi B; Liu J; Wu J; Zhou F; He Z; Fan J; Wang W; Feng H; Yao S; Keegan P; Huang Y; Guo J
    Clin Cancer Res; 2022 Feb; 28(3):489-497. PubMed ID: 34740921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
    Si L; Zhang X; Shu Y; Pan H; Wu D; Liu J; Mao L; Wang X; Wen X; Gu Y; Zhu L; Lan S; Cai X; Diede SJ; Dai H; Niu C; Li J; Guo J
    Front Immunol; 2022; 13():882471. PubMed ID: 36304457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
    Li S; Wu X; Yan X; Zhou L; Chi Z; Si L; Cui C; Tang B; Mao L; Lian B; Wang X; Bai X; Dai J; Kong Y; Tang X; Feng H; Yao S; Flaherty KT; Guo J; Sheng X
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
    Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
    Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
    Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
    Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
    Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.
    Yang J; Dong L; Yang S; Han X; Han Y; Jiang S; Yao J; Zhang Z; Zhang S; Liu P; Qin Y; Wu H; Feng H; Yao S; Sun Y; Song H; Shi Y
    Eur J Cancer; 2020 May; 130():182-192. PubMed ID: 32224416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
    Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
    EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
    Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
    Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
    Lian B; Li Z; Wu N; Li M; Chen X; Zheng H; Gao M; Wang D; Sheng X; Tian H; Si L; Chi Z; Wang X; Lai Y; Sun T; Zhang Q; Kong Y; Long GV; Guo J; Cui C
    Ann Oncol; 2024 Feb; 35(2):211-220. PubMed ID: 37956739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.
    Du Y; Dai J; Mao L; Wei X; Bai X; Chen L; Lin J; Chi Z; Cui C; Sheng X; Lian B; Tang B; Wang X; Yan X; Li S; Zhou L; Guo J; Chen Y; Si L
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):93-101. PubMed ID: 37625814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toripalimab for the treatment of melanoma.
    Tang B; Chi Z; Guo J
    Expert Opin Biol Ther; 2020 Aug; 20(8):863-869. PubMed ID: 32406293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.